Drug Discovery World, Drug Discovery and Development News

Building new models of drug discovery in Europe the Innovative Medicines Initiative

By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman

The development of a new medicine is risky and expensive. It often takes 15 years and a $1billion investment for a compound to navigate its way along the development process. Only 8% of candidates make it to market and benefiting the patient.

Collaboration for innovation is the new mantra for the pharmaceutical industry

By Professor Jackie Hunter

In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain. The need to identify sources of knowledge and expertise outside of their own organisations is paramount.

Could the keys to precision and personalised medicine be rooted in predictive safety and research methods?

By Robert G. Hunter

To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care.

Developing the first treatment for Acute Kidney Injury

By Tim Knotnerus

Acute Kidney Injury (AKI) is a devastating disease characterised by a rapid loss of kidney function resulting in inability to maintain fluid, electrolyte and acidbase balance. AKI is particularly common in patients admitted to the Intensive Care Unit where incidence rates between 22% to as high as 67% of admissions have been reported.

How digital innovation and collaboration is driving a global demand for effective reporting in research funding

By Frances Buck

The UK, Europe and the US are world leaders in research and innovation. They have world-leading universities, research institutes and scientific enterprises, supported by a public and private sector that has continued to invest, despite the global economic downturn.

Long live peptides evolution of peptide half-life extension technologies and emerging hybrid approaches

By Dr Ronald V. Swanson

Among therapeutic modalities, peptides occupy a middle ground between traditional âsmall moleculeâ drugs and the larger injectable biologics, not fitting comfortably into either category.

Rules for drug discovery: can simple property criteria help you to find a drug?

By Dr Matthew Segall

Since publication of Lipinskiâs Rule of Five (Ro5) in 1997 we have seen the growth of a minor industry dedicated to generating new ârulesâ for drug discovery. Fuelled by âRo5 envyâ, these rules are usually based on simple calculated compound characteristics and define criteria for the selection of compounds in drug discovery. But, can a generic rule be used to reliably select compounds for drug discovery?

The current status of non-biopharma drug discovery

By Dr John Comley

Screening centres in academic institutions and non-profit organisations have become an established mechanism to exploit novel targets and neglected diseases and to identify chemical probes. Where centres have a disease focus, their main expertise resides in cancer and phenotypic screens, with screening experience greatest for kinases, phenotypic approaches and protein-protein interactions.

Nanofiber Solutions Fills Void in Market with Updated 3D Cell Culture Plate

May 2014

Innovative technology provides a 3D environment for cellsInnovative technology provides a 3D environment for cells

Hamilton Launches Compact BiOS Automated SystemsThat Store 100K to More Than 1MM Samples

May 2014

More labs now have access to next-generation sample storage to improve sample integrity

High Integrity Sample Storage Ensured By Double O-Ring Sea

Porvair Sciences has introduced new silicone cap mats for its range of 2ml deep well storage blocks.

	Drug Discovery	Business	Chemistry	Enabling Technologies
	Informatics	Personalised Medicine	Screening	Therapeutics